NCT06884163 Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics
| NCT ID | NCT06884163 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Hand Eczema |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-01-13 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study explores the immune landscape of chronic hand eczema using spatial transcriptomics and single-cell proteomics, offering new insights into disease mechanisms and potential therapeutic targets.
Eligibility Criteria
Inclusion Criteria: * Patients affected with chronic hand eczema of endogenous and/or exogenous origin, age from 18 to 65 years * Patients affected with eczema located on the hands for at least 3 months or with ≥ 2 disease flare-ups in the last year. * Patients affected with atopic dermatitis affecting the hands and other areas of the body, provided the eczema lesions involve less than 30% of the body surface area. Exclusion Criteria: * Concurrent or previous treatment with immunosuppressants, except for short courses of systemic corticosteroids (less than one month of continuous treatment), or biologic agents that may affect the clinical aspects or progression of chronic hand eczema. * Patients who have received systemic corticosteroids within one month prior to enrollment in the study. * Patients using topical corticosteroids or calcineurin inhibitors within one week of study enrollment (this time frame is considered to provide a good balance between potential residual pharmacological effects and ethical considerations). * Patients with chronic hand eczema of mixed etiology (e.g., allergic and atopic) or those considered "etiologically unclassifiable" will not be included in the data analysis.
Contact & Investigator
Ketty Peris, Prof
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06884163 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Hand Eczema. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06884163 currently recruiting?
Yes, NCT06884163 is actively recruiting participants. Contact the research team at ketty.peris@policlinicogemelli.it for enrollment information.
Where is the NCT06884163 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06884163 clinical trial?
NCT06884163 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Ketty Peris, Prof at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.